Outcome |
Relative effect (95% CI) |
Absolute effect (95% CI)1 |
Certainty of the Evidence (GRADE) |
Clinical improvement D28 |
RR: 1.28 (0.97 - 1.70) |
140 more per 1000 (from 15 fewer to 350 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
1 trials
Lonze B, 2022
152 participants
|
|
Clazakizumab 640 per 1,000 (485 - 850) |
Placebo 500 per 1,000 |
|
Clinical improvement D60 |
RR: 1.28 (0.99 - 1.66) |
151 more per 1000 (from 5 fewer to 357 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
1 trials
Lonze B, 2022
152 participants
|
|
Clazakizumab 692 per 1,000 (535 - 897) |
Placebo 541 per 1,000 |
|
WHO progression score (level 7 or above) D28 |
RR: 0.66 (0.43 - 1.01) |
152 fewer per 1000 (from 254 fewer to 4 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
1 trials
Lonze B, 2022
152 participants
|
|
Clazakizumab 294 per 1,000 (192 - 450) |
Placebo 446 per 1,000 |
|
WHO progression score (level 7 or above) D60 |
Outcome not yet measured or reported
|
|
All-cause mortality D28 |
RR: 0.91 (0.54 - 1.55) |
23 fewer per 1000 (from 116 fewer to 139 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious studies from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Jordan S, 2021; Lonze B, 2022
169 participants
|
|
Clazakizumab 230 per 1,000 (137 - 392) |
Placebo 253 per 1,000 |
|
All-cause mortality D60 |
RR: 0.77 (0.49 - 1.19) |
83 fewer per 1000 (from 184 fewer to 69 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious studies from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Jordan S, 2021; Lonze B, 2022
169 participants
|
|
Clazakizumab 278 per 1,000 (177 - 430) |
Placebo 361 per 1,000 |
|
Viral negative conversion D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
RR: 1.13 (0.20 - 6.24) |
27 more per 1000 (from 178 fewer to 1000 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious We presume that the adverse event rates and the corresponding relative risks, are similar across diverse settings, therefore not downgraded for indirectness Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
1 trials
Jordan S, 2021
17 participants
|
|
Clazakizumab 249 per 1,000 (44 - 1000) |
Placebo 222 per 1,000 |
|
Serious adverse events
|
RR: 0.69 (0.46 - 1.04) |
134 fewer per 1000 (from 234 fewer to 17 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious We presume that the adverse event rates and the corresponding relative risks, are similar across diverse settings, therefore not downgraded for indirectness Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Jordan S, 2021; Lonze B, 2022
169 participants
|
|
Clazakizumab 299 per 1,000 (200 - 451) |
Placebo 434 per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect